Rhabdoid tumors of the liver: Rare, aggressive, and poorly responsive to standard cytotoxic chemotherapy

Pediatric Blood and Cancer

Volumn 57, Issue 3, 2011, Pages 423-428

  Trobaugh Lotrario, Angela D ^a   Finegold, Milton J ^b   Feusner, James H ^c  

^a Sacred Heart Children's Hospital   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CHILDREN S HOSPITAL OAKLAND   (United States)

Author keywords

Liver; Pediatric; Rhabdoid tumor

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; LIVER RESECTION; LIVER TRANSPLANTATION; LIVER TUMOR; MALE; MEDICAL RECORD REVIEW; METASTASIS; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHABDOID TUMOR; SCHOOL CHILD; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHROMOSOMAL PROTEINS, NON-HISTONE; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LIVER NEOPLASMS; PROGNOSIS; RARE DISEASES; RHABDOID TUMOR; TRANSCRIPTION FACTORS;

EID: 79960183290     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22857     Document Type: Article

References (38)

1. Garces-Inigo E, Leung R, Sebire N, et al. Extrarenal rhabdoid tumors outside the central nervous system. Pediatr Radiol 2009; 39: 817-822.
2. Wu X, Dagar V, Algar E, et al. Rhabdoid tumour: A malignancy of early childhood with variable primary site, histology and clinical behaviour. Pathology 2008; 40: 664-670.
3. Ravindra K, Cullinane C, Lewis I, et al. Long-term survival after spontaneous rupture of a malignant rhabdoid tumor of the liver. J Pediatr Surg 2002; 37: 1488-1490.
4. Scheimberg I, Cullinane C, Kelsey A, et al. Primary hepatic malignant tumor with rhabdoid features: A histological, immunocytochemical and electron microscopic study of four cases and a review of the literature. Am J Surg Pathol 1996; 20: 1394-1400.
5. Jayaram A, Finegold M, Parham D, et al. Successful management of rhabdoid tumor of the liver. J Pediatr Hematol Oncol 2007; 29: 406-408.
6. Ohyama M, Ijiri R, Tanaka Y, et al. Congenital primitive epithelial tumor of the liver showing focal rhabdoid features, placental involvement, and clinical features mimicking multifocal hemangioma or stage 4S neuroblastoma. Hum Pathol 2000; 31: 259-263.
7. Kuroda H, Moritake H, Sawada K, et al. Establishment of a cell line from a malignant rhabdoid tumor of the liver lacking the function of two tumor suppressor genes, hSNF5/INI1 and p16 Cancer Genet Cytogenet 2005; 158: 172-179.
8. Kelly D, Jones M, Humphreys S, et al. Spontaneous rupture of a malignant rhabdoid tumour of the liver. Pediatr Surg Int 1998; 14: 111-112.
9. Wagner L, Garrett J, Ballard E, et al. Malignant rhabdoid tumor mimicking hepatoblastoma: A case report and literature review. Pediatr Dev Pathol 2007; 10: 409-415.
10. Parham D, Peiper S, Robicheaux G, et al. Malignant rhabdoid tumor of the liver. Arch Pathol Lab Med 1988; 112: 61-64.
11. Gururangan S, Bowman L, Parham D, et al. Primary extracranial rhabdoid tumors. Cancer 1993; 71: 2653-2659.
12. Foschini M, Van Eyken P, Brock P, et al. Malignant rhabdoid tumour of the liver. A case report. Histopathology 1992; 20: 157-165.
13. Hunt S, Anderson W. Malignant rhabdoid tumor of the liver. Am Soc Clin Pathol 1990; 94: 645-648.
14. Madigan C, Armenian S, Malogolowkin M, et al. Extracranial malignant rhabdoid tumors in childhood. Cancer 2007; 110: 2061-2066.
15. DiCori S, Oudjhane K, Neilson K. Primary malignant rhabdoid tumour of the liver. Can Assoc Radiol J 1993; 44: 52-54.
16. Al Nassan A, Sughayer M, Matalka I, et al. INI1 (BAF47) immunohistochemistry is an essential diagnostic tool for children with hepatic tumors and low alpha fetoprotein. J Pediatr Hematol Oncol 2010; 32: e79-e81.
17. Yuri T, Danbara M, Shikata N, et al. Malignant rhabdoid tumor of the liver: Case report and literature review. Pathol Int 2004; 54: 623-629.
18. Gonzalez-Crussi F, Goldschmidt R, Hsueh W, et al. Infantile sarcoma with intracytoplasmic filamentous inclusions: Distinctive tumor of possible histiocytic origin. Cancer 1982; 49: 2365-2375.
19. Kaiserling E, Ruck P, Handgretinger R, et al. Immunohistochemical and cytogenetic findings in malignant rhabdoid tumor. Gen Diagn Pathol 1995/1996; 141: 327-337.
20. Donner L, Rao A, Truss L, et al. Translocation (8;13)(q24.2;q33) in a malignant rhabdoid tumor of the liver. Cancer Genet Cytogenet 2000; 116: 153-157.
21. Pogacnik A. Malignant rhabdoid tumor of the liver diagnosed by fine needle aspiration cytology. Acta Cytol 1997; 41: 539-543.
22. Katzenstein H, Kletzel M, Reynolds M, et al. Metastatic malignant rhabdoid tumor of the liver treated with tandem high-dose therapy and autologous peripheral blood stem cell rescue. Med Pediatr Oncol 2003; 40: 199-201.
23. Weyman C, Dolson L, Kedar A. Secretion of vasointestinal peptide by a primary liver tumor with rhabdoid features. J Surg Oncol 1993; 54: 267-270.
24. Jimenez-Heffernan J, Lopez-Ferrer P, Burgos E, et al. Pathological case of the month. Arch Pediatr Adolesc Med 1998; 152: 509-510.
25. Marzano E, Lermite E, Nobili C, et al. Malignant rhabdoid tumour of the liver in the young adult: Report of first two cases. HPB Surg 2009; 2009: 1-4.
26. Fuchs J, Rydzynski J, Von Schwinitz D, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma. Cancer 2002; 95: 172-182.
27. Jung S, Kim K, Kim M, et al. Clinical characteristics and prognosis of patients with hepatoblastoma. World J Surg 2001; 25: 126-130.
28. Trobaugh-Lotrario A, Tomlinson G, Finegold M, et al. Small cell undifferentiated variant of hepatoblastoma: Adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer 2009; 52: 328-334.
29. Roberts C, Biegel J. The role of SMARCB1/INI1 in development of rhabdoid tumor. Cancer Biol Ther 2009; 8: 412-414.
30. Biegel J, Zhou J, Rorke L, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999; 59: 74-79.
31. Mueller W, Eum H, Lass U, et al. No evidence of hSNF5/INI1 point mutations in choroid plexus papilloma. Am J Hum Genet 1999; 65: 1342-1348.
32. Jackson E, Shaikh T, Gururangan S, et al. High-density single nucleotide polymorphism array analysis in patients with germline deletions of 22q11.2 and malignant rhabdoid tumor. Hum Genet 2007; 122: 117-127.
33. Savla J, Chen T, Schneider N, et al. Mutations of the hSNF5/INI1 gene in renal rhabdoid tumors with second primary brain tumors. J Natl Cancer Inst 2000; 92: 648-650.
34. Yamamoto M, Suzuki N, Katakeyama N, et al. Treatment of stage IV malignant rhabdoid tumor of the kidney (MRTK) with ICE and FDCy. J Pediatr Hematol Oncol 2006; 28: 286-289.
35. Waldron P, Rodgers B, Kelly M, et al. Successful treatment of a patient with stage IV rhabdoid tumor of the kidney: Case report and review. J Pediatr Hematol Oncol 1999; 21: 53-57.
36. Wagner L, Hill D, Fuller C, et al. Treatment of metastatic rhabdoid tumor of the kidney. J Pediatr Hematol Oncol 2002; 24: 385-388.
37. Gadd S, Sredni S, Huang C, et al. Rhabdoid tumor: Gene expression clues to pathologenesis and potential therapeutic targets. Lab Invest 2010; 90: 724-738.
38. Algar E, Muscat A, Dagar V, et al. Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. PLoS One 2009; 4: e4482.